Abstract Recent FDA approval of new GLP-1 agonists drugs focused on weight loss has been met with a surge in use of drugs such as Wegovy and Zebound
Molecular and genetic characterization of depression: overlap with other psychiatric disorders and aging
Data extraction Two designated authors (AM and SS) meticulously extracted pertinent data from the included studies, including authorship details, publication timeline, samples of the study, mean demographic parameters (e.g., age, sex, baseline weight, and baseline BMI), type of bariatric surgery, prevalent background diseases, type of the GLP-1RAs therapy, the time of the initiation of the medical treatment, laboratory indices, amount of weight-change, and a comprehensive array of outcome measures, such as nausea, vomiting, diarrhea, and serious adverse events
Cellular Migration & Repair: Explored for combined activity in upregulating actin sequestration (cell motility), modulating inflammatory markers, and accelerating overall wound closure in vitro
It is important in fatty acids burning and transforming them into energy
Practical notes: most studies use ubiquinone, co-administer with dietary fat, and review potential interactions, especially with lipid-lowering therapy
